Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

10.1016/S0140-6736(95)91325-4

Carlsson A, 1995, Int Clin Psychopharmacol, 10, 21

10.1176/ajp.151.10.1409

10.1093/schbul/13.1.133

Gerlach J, 1995, Int Clin Psychopharmacol, 10, 39

10.1016/0893-133X(94)00129-N

10.1007/BF02246146

Kay SR, 1986, Fiszbein A: Positive and Negative Syndrome Scale (PANSS) Manual

10.1192/bjp.134.4.382

Guy, 1976, Md, 217

Association for Methodology and Documentation in Psychiatry (Arbeltsgemeinschaft, 1981, Berlin

10.1111/j.1600-0447.1970.tb02066.x

10.1192/bjp.154.5.672

Coding Symbol, 1990, US Department of Health and Human Services

10.1001/archpsyc.1991.01810270051007

10.1093/schbul/11.3.471

10.1097/00005053-198506000-00001

10.1176/ajp.152.1.153

Siris SG, 1995, Schizophrenia, 128

Casey DE, 1995, Int Clin Psychopharmacol, 10, 105

10.1007/BF00442559

10.1001/archpsyc.1988.01800330013001

10.1056/NEJM199601043340109

10.1126/science.3854

10.1016/0893-133X(95)00069-P

10.1016/0024-3205(94)00739-X

10.1097/00004850-199400920-00001

Beasley, Hamilton SH

10.1007/BF02245617

10.1016/0893-133X(94)00130-R

10.1016/S0893-133X(96)00218-7

10.1007/BF02245615

Goff DC, 1995, Schizophrenia, 566

10.1007/BF00217059

10.3181/00379727-131-33931

Fischer V, 1991, Mol Pharmacol, 40, 2641

10.2165/00002018-199200071-00011

10.1176/ajp.149.1.68

10.1192/bjp.166.6.712